Treatment of children with medulloblastoma without metastatic involvement in the age group older than 3 years: International experience and results...
Левашов А. С., Загидуллина С. Р., Строганова А. М., Хоченков Д. А., Рyжова М. В., Горелyшев С. К., Кадиров С. У., Бабелян С. С., Григоренко В. А., Сидельников Д. А., Субботина Н. Н., Дайлидите В. В., Менткевич Г. Л.
Современная онкология
Т. 22, Вып. 1, С. 42-52
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.26442/18151434.2020.1.200014
Аннотация:
Background. During the past 20 years, some large international studies have been conducted that evaluated the effectiveness of treatment programs for children with medulloblastoma. At the same time, in the standard risk group, fairly high rates of 5-year overall survival (OS) and event-free survival (EFS) were achieved, which amounted to 85[%] and 80[%], respectively. At the present time some risk-adaptive therapeutic programs are developed according to molecular-biological features of tumor cells and possibility of chemotherapy and craniospinal radiation (CSI) therapy dose reduction. Materials and methods. From 2008 to 2018 fifty one pediatric patients with primary diagnosed medulloblastoma in the age group 3–18 years were included in trial, 38 in standard risk group, 13 in high risk group (without metastatic disease). Treatment program consisted of surgical removal of the primary tumor site with subsequent chemotherapy (with high-dose cyclophosphamide or thiophosphamide) and radiation th
Ключевые слова:
Children; Craniospinal radiation; High-dose chemotherapy; Medulloblastoma; Molecular biological factors; Prognosis; Standard and high risk group
Язык текста: Русский
ISSN: 1815-1434
Левашов А. С.
Загидуллина С. Р.
Строганова А. М.
Хоченков Д. А.
Рyжова М. В.
Горелyшев С. К.
Кадиров С. У.
Бабелян С. С.
Григоренко В. А.
Сидельников Д. А. Дмитрий Андреевич 1996-
Субботина Н. Н.
Дайлидите В. В.
Менткевич Г. Л.
Levashov A. S.
Zagidullina S. R.
Stroganova A. M.
Khochenkov D. A.
Ryzhova M. V.
Gorelyshev S. K.
Kadirov S. U.
Babelyan S. S.
Grigorenko V. A.
Sidel`nikov D. A. Dmitrij Andreevich 1996-
Subbotina N. N.
Daylidite V. V.
Mentkevich G. L.
Treatment of children with medulloblastoma without metastatic involvement in the age group older than 3 years: International experience and results of intercenter trial [Лечение детей с медуллобластомой без метастатического поражения в возрастной группе старше 3 лет: международный опыт и результаты межцентрового исследования]
Treatment of children with medulloblastoma without metastatic involvement in the age group older than 3 years: International experience and results...
Текст визуальный непосредственный
Современная онкология
Медицинское маркетинговое агентство "МедиаМедика"
Т. 22, Вып. 1 С. 42-52
2020
Статья
Children Craniospinal radiation High-dose chemotherapy Medulloblastoma Molecular biological factors Prognosis Standard and high risk group
Background. During the past 20 years, some large international studies have been conducted that evaluated the effectiveness of treatment programs for children with medulloblastoma. At the same time, in the standard risk group, fairly high rates of 5-year overall survival (OS) and event-free survival (EFS) were achieved, which amounted to 85[%] and 80[%], respectively. At the present time some risk-adaptive therapeutic programs are developed according to molecular-biological features of tumor cells and possibility of chemotherapy and craniospinal radiation (CSI) therapy dose reduction. Materials and methods. From 2008 to 2018 fifty one pediatric patients with primary diagnosed medulloblastoma in the age group 3–18 years were included in trial, 38 in standard risk group, 13 in high risk group (without metastatic disease). Treatment program consisted of surgical removal of the primary tumor site with subsequent chemotherapy (with high-dose cyclophosphamide or thiophosphamide) and radiation th